Positive results from the VOICE study have been published for Vafseo® (vadadustat), a medicine from the MEDICE Health Family for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD). Conducted by U.S. Renal Care (USRC) and Akebia Therapeutics, the study evaluated the safety and efficacy of administering Vafseo® three times weekly in patients with end-stage kidney disease receiving haemodialysis in dialysis centres.
A total of 2,116 patients participated in the study. Treatment with Vafseo® was compared with the previous standard of care based on erythropoiesis-stimulating agents (ESAs). The primary endpoint included all-cause mortality and hospitalisations, irrespective of cause.
The results of the planned interim analysis were unexpectedly positive: Vafseo® met the primary endpoint and demonstrated superiority over the previous standard therapy. This outcome was primarily driven by a statistically significant 10% reduction in the rate of hospitalisations. In light of these compelling findings, both the independent Data Monitoring Committee and the Steering Committee recommended the early termination of the study.
:focal()){kind=logo}